Clinical Trial Update: PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating misoprostol for prevention of recurrent Clostridium difficile infection was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection

Drugs mentioned

• MISOPROSTOL (Misoprostol)

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Clostridium Difficile | Phase 2 | Status: TERMINATED | Results posted: 2022-11-30